Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Condition(s):Mild to Moderate Diabetic Sensorimotor PolyneuropathyLast Updated:February 21, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Mild to Moderate Diabetic Sensorimotor PolyneuropathyLast Updated:February 21, 2019Completed
Condition(s):Diabetic NeuropathyLast Updated:January 14, 2008Completed
Condition(s):Complications of Diabetes Mellitus; Diabetic NeuropathiesLast Updated:March 24, 2014Completed
Condition(s):Diabetic PolyneuropathyLast Updated:May 5, 2016Completed
Condition(s):Diabetes Mellitus; Painful Distal Symmetric Sensorimotor PolyneuropathyLast Updated:January 18, 2013Unknown status
Condition(s):DiabetesLast Updated:February 15, 2010Completed
Condition(s):Autonomic Nervous System Disease; Amyloid NeuropathiesLast Updated:October 21, 2021Unknown status
Condition(s):Diabetic NeuropathyLast Updated:September 27, 2016Completed
Condition(s):Neuropathy Autonomic; Cardiac Autonomic Neuropathy; Type2Diabetes; Diabetic Neuropathy Peripheral; Diabetic NeuropathiesLast Updated:April 6, 2022Completed
Condition(s):Pediatric Cancer; Pediatric Brain Tumor; Chemotherapy-induced Peripheral Neuropathy; Sensorimotor PolyneuropathyLast Updated:April 19, 2019Suspended
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.